- Company
- SK Bioscience wins 2nd trial on pneumococcal patent dispute
- by Kim, Jin-Gu Dec 4, 2024 05:56am
- &160; SK Bioscience has won the second trial of its patent infringement lawsuit against Pfizer over its pneumococcal vaccine, overturning the ruling made in the first trial.&160; The two companies have been engaged in a long-running lawsuit over SK Bioscience's 13-valent pneumococcal vaccine, ‘Skypheumo Prefilled Syringe (Skypheumo).’
- Company
- Sanofi announces entering the RSV vacc. market for children
- by Whang, byung-woo Dec 4, 2024 05:56am
- Sanofi has announced the launch of Beyfortus, an injectable antibody drug to prevent respiratory syncytial virus (RSV) lower respiratory tract disease, for the first time in South Korea. The company aims to take a market share. As clinical practices are in high demand for the vaccine, proactive RSV prevention will become possible following th
- Company
- GSK seeks HIV paradigm shift with long-acting injectable
- by Whang, byung-woo Dec 4, 2024 05:56am
- With the long-acting HIV drug Vocabria+Rekambys combination therapy seeking insurance reimbursement coverage, attention is being paid to whether the drug’s introduction will bring about a shift in the treatment environment. According to industry sources on the 3rd, GSK Korea has completed pharmacoeconomic evaluations for its new HIV dru
- Company
- 4 out of 5 pharmas saw export sales expanded
- by Kim, Jin-Gu Dec 3, 2024 05:53am
- Export sales of four out of five pharmaceutical and biotech companies have increased year-over-year (YoY). The net export sales of 28 major pharmaceutical companies increased from KRW 5.3405 trillion to KRW 6.6449 trillion over a year, up 25.6%. Samsung Biologics' export sales increased by over KRW 600 billion. Export sales of Celltrion
- Company
- Reasonable compromise between industry-govt is key
- by Eo, Yun-Ho Dec 3, 2024 05:52am
- The pharmacoeconomic evaluation exemption system has received unflattering attention since its implementation. It is no wonder that the government has been gathering voices in support of its 'reduction' under the pretense of 'improvement'. The PE exemption system is the only system in Korea's insurance policy landscape that helps patients
- Company
- Promotion of new drugs·biosimilars at KOS annual conference
- by Son, Hyung Min Dec 2, 2024 05:49am
- Korean and international pharmaceutical and biotech industries are fiercely competing for marketing in the market for macular degeneration. Global companies, including Novartis, Roche, and Bayer, and Korean pharmaceutical companies, including Kukje Pharm, Samil Pharm, and Chong Kun Dang, have participated in the annual meeting of the Korean
- Company
- Antibody drug 'Fasenra' lands in KOR with EGPA indication
- by Eo, Yun-Ho Dec 2, 2024 05:49am
- Astra Zeneca's Fasenra, an antibody drug for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), is expected to be introduced in South Korea. According to industry sources on November 29, Astra Zeneca Korea has recently submitted an application to the Ministry of Food and Drug Safety (MFDS) for an expanded indication of
- Company
- Industry speeds up the development of bispecific antibodies
- by Son, Hyung Min Dec 2, 2024 05:49am
- The Korean pharmaceutical industry is accelerating the clinical trials of bispecific antibodies to secure solid tumor indications. Bispecific antibodies, which have an additional specific antigen binding site compared to monoclonal antibodies, are recognized for their clinical benefits. GC Biopharma, Hanmi Pharmaceutical, ABL Bio, and Immuneonci
- Company
- Is RWD needed for post-listing control of PE exempt drugs?
- by Eo, Yun-Ho Dec 2, 2024 05:49am
- The budget is tight, but the use of high-priced drugs continues to rise. The government is beginning to feel the strain of the systems it has put in place to increase access to new drugs, especially the pharmacoeconomic evaluation (PE) exemption system, which is increasingly being utilized and being subject to criticism. "The purpose of
- Company
- oHCM drug 'Camzyos' gets greenlight for reimb
- by Eo, Yun-Ho Nov 29, 2024 05:55am
- 'Camzyos,' a new drug to treat obstructive hypertrophic cardiomyopathy (oHCM), will finally be listed for reimbursement. The Ministry of Health and Welfare (MOHW) held the 23rd Health Insurance Policy Review Committee meeting on November 28, announcing that BMS Korea’s Camzyos (mavacamten), a new drug used to treat obstructive hypertroph
